Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.
2.

Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.

Wang Y, Liu Y, Bailey C, Zhang H, He M, Sun D, Zhang P, Parkin B, Baer MR, Zheng P, Malek SN, Liu Y.

Oncogene. 2020 Apr;39(14):3015-3027. doi: 10.1038/s41388-020-1201-z. Epub 2020 Feb 15.

PMID:
32060420
3.

Jumping translocations of chromosome 1q occurring by a multi-stage process in an acute myeloid leukemia progressed from myelodysplastic syndrome with a TET2 mutation.

Lee I, Gudipati MA, Waters E, Duong VH, Baer MR, Zou Y.

Mol Cytogenet. 2019 Nov 19;12:47. doi: 10.1186/s13039-019-0460-2. eCollection 2019.

4.

Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia.

Holtzman NG, El Chaer F, Baer MR, Ali O, Patel A, Duong VH, Sausville EA, Singh ZN, Koka R, Zou YS, Etemadi A, Emadi A.

Br J Haematol. 2020 Mar;188(6):881-887. doi: 10.1111/bjh.16261. Epub 2019 Dec 5.

PMID:
31804722
5.

An unusual presentation of paroxysmal nocturnal haemoglobinuria.

Sanchez-Petitto G, Drachenberg CB, Mannuel HD, Law JY, Zimrin AB, Baer MR.

Br J Haematol. 2020 Feb;188(3):347. doi: 10.1111/bjh.16250. Epub 2019 Nov 21. No abstract available.

PMID:
31750542
6.

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance).

Klepin HD, Ritchie E, Major-Elechi B, Le-Rademacher J, Seisler D, Storrick L, Sanford BL, Marcucci G, Zhao W, Geyer SA, Ballman KV, Powell BL, Baer MR, Stock W, Cohen HJ, Stone RM, Larson RA, Uy GL.

J Geriatr Oncol. 2020 Jan;11(1):107-113. doi: 10.1016/j.jgo.2019.10.002. Epub 2019 Oct 24.

PMID:
31668825
7.

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ.

N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.

PMID:
31665578
8.

A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.

Pratz KW, Rudek MA, Smith BD, Karp J, Gojo I, Dezern A, Jones RJ, Greer J, Gocke C, Baer MR, Duong VH, Rosner G, Zahurak M, Wright JJ, Emadi A, Levis M; ETCTN-8922 study team.

Biol Blood Marrow Transplant. 2020 Feb;26(2):300-306. doi: 10.1016/j.bbmt.2019.09.023. Epub 2019 Sep 21.

9.

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R.

Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428.

10.

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.

Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R.

Leukemia. 2019 Dec;33(12):2974-2978. doi: 10.1038/s41375-019-0524-7. Epub 2019 Jul 30. No abstract available.

11.

Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma.

Duong VH, Holtzman NG, Koka R, Singh ZN, Zou Y, Emadi A, Rapoport AP, Kocoglu MH, Baer MR, Badros AZ.

Leuk Lymphoma. 2019 Dec;60(14):3577-3580. doi: 10.1080/10428194.2019.1633639. Epub 2019 Jul 8. No abstract available.

PMID:
31282234
12.
13.

Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.

Patel A, Williams H, Baer MR, Zimrin AB, Law JY.

Acta Haematol. 2019;142(4):233-238. doi: 10.1159/000500223. Epub 2019 May 20.

PMID:
31108496
14.

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain N.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):431-440.e13. doi: 10.1016/j.clml.2019.03.015. Epub 2019 Mar 26.

PMID:
31056348
15.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study.

Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ.

Haematologica. 2020 Jan;105(1):161-169. doi: 10.3324/haematol.2018.208678. Epub 2019 Apr 19.

16.

Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.

Adige S, Lapidus RG, Carter-Cooper BA, Duffy A, Patzke C, Law JY, Baer MR, Ambulos NP, Zou Y, Bentzen SM, Emadi A.

Cancer Chemother Pharmacol. 2019 Jun;83(6):1105-1112. doi: 10.1007/s00280-019-03825-2. Epub 2019 Apr 9. Review.

PMID:
30968179
17.

Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD.

Dellomo AJ, Baer MR, Rassool FV.

Cancer Lett. 2019 Jul 10;454:171-178. doi: 10.1016/j.canlet.2019.03.048. Epub 2019 Apr 4.

PMID:
30953707
18.

Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.

Bade NA, Lu C, Patzke CL, Baer MR, Duong VH, Law JY, Lee ST, Sausville EA, Zimrin AB, Duffy AP, Lawson J, Emadi A.

J Oncol Pharm Pract. 2020 Jan;26(1):74-92. doi: 10.1177/1078155219838316. Epub 2019 Mar 27.

PMID:
30917738
19.

Babesiosis Masquerading as Evans Syndrome.

Elder SA, O'Brien JJ, Singh ZN, Wilding E, Zimrin AB, Law JY, Baer MR.

Am J Med. 2019 Jul;132(7):e616-e617. doi: 10.1016/j.amjmed.2019.02.041. Epub 2019 Mar 20. No abstract available.

PMID:
30904506
20.

Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.

El Chaer F, Holtzman NG, Sausville EA, Law JY, Lee ST, Duong VH, Baer MR, Koka R, Singh ZN, Hardy NM, Emadi A.

Acta Haematol. 2019;141(2):107-110. doi: 10.1159/000495558. Epub 2019 Jan 29.

PMID:
30695783
21.

Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.

Kogan AA, Lapidus RG, Baer MR, Rassool FV.

Adv Cancer Res. 2019;141:213-253. doi: 10.1016/bs.acr.2018.12.005. Epub 2019 Jan 21.

PMID:
30691684
22.

Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.

Mascarenhas J, Baer MR, Kessler C, Hexner E, Tremblay D, Price L, Sandy L, Weinberg R, Pahl H, Silverman LR, Goldberg JD, Kosiorek H, Dueck AC, Hoffman R.

Leuk Lymphoma. 2019 May;60(5):1343-1345. doi: 10.1080/10428194.2018.1532509. Epub 2019 Jan 22. No abstract available.

PMID:
30668266
23.

Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab.

El Chaer F, Ali OM, Sausville EA, Law JY, Lee ST, Duong VH, Baer MR, Koka R, Singh ZN, Wong J, Yared JA, Griffiths EA, Emadi A.

Am J Hematol. 2019 Jan;94(1):E7-E8. doi: 10.1002/ajh.25317. Epub 2018 Nov 25. No abstract available.

24.

High-Risk Acute Promyelocytic Leukemia with Unusual T/Myeloid Immunophenotype Successfully Treated with ATRA and Arsenic Trioxide-Based Regimen.

Singh ZN, Duong VH, Koka R, Zou Y, Sawhney S, Tang L, Baer MR, Ambulos N, El Chaer F, Emadi A.

J Hematop. 2018 Sep;11(3):67-74. doi: 10.1007/s12308-018-0329-z. Epub 2018 Aug 9.

25.

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.

Talpaz M, Erickson-Viitanen S, Hou K, Hamburg S, Baer MR.

J Hematol Oncol. 2018 Aug 7;11(1):101. doi: 10.1186/s13045-018-0642-0.

26.

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.

Berdeja J, Palandri F, Baer MR, Quick D, Kiladjian JJ, Martinelli G, Verma A, Hamid O, Walgren R, Pitou C, Li PL, Gerds AT.

Leuk Res. 2018 Aug;71:82-88. doi: 10.1016/j.leukres.2018.06.014. Epub 2018 Jun 30.

PMID:
30025280
27.

Cryptic ETV6-PDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome/myeloproliferative neoplasm.

Singh ZN, Richards S, El Chaer F, Duong VH, Gudipati MA, Waters EO, Koon S, Webley M, Pitel B, Hoppman NL, Baer MR, Zou YS.

Leuk Lymphoma. 2019 May;60(5):1304-1307. doi: 10.1080/10428194.2018.1480774. Epub 2018 Jul 11. No abstract available.

PMID:
29992858
28.

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.

Vasu S, Kohlschmidt J, Mrózek K, Eisfeld AK, Nicolet D, Sterling LJ, Becker H, Metzeler KH, Papaioannou D, Powell BL, Kolitz JE, Moore JO, Baer MR, Roboz GJ, Stone RM, Byrd JC, Carroll AJ, Bloomfield CD.

Blood Adv. 2018 Jul 10;2(13):1645-1650. doi: 10.1182/bloodadvances.2017015222.

29.

Sickle Cell Disease Complicated by Iron Overload: An Under-Recognized Risk Factor for Vibrio vulnificus Infection.

El Chaer F, Holtzman NG, Baer MR, Zimrin AB, Law JY.

Acta Haematol. 2018;139(3):199-200. doi: 10.1159/000488754. Epub 2018 May 7. No abstract available.

30.

Acute Onset Unilateral Proptosis.

El Chaer F, Singh ZN, Zou Y, Mohindra P, Baer MR, Law JY.

Am J Med. 2018 Aug;131(8):e337-e338. doi: 10.1016/j.amjmed.2018.03.021. Epub 2018 Apr 13. No abstract available.

PMID:
29660350
31.

Thrombotic microangiopathy in the setting of human immunodeficiency virus infection: High incidence of severe thrombocytopenia.

Bade NA, Giffi VS, Baer MR, Zimrin AB, Law JY.

J Clin Apher. 2018 Jun;33(3):342-348. doi: 10.1002/jca.21615. Epub 2018 Jan 26.

PMID:
29377224
32.

Intravenous immunoglobulin as salvage therapy for refractory thrombotic thrombocytopenic purpura.

Ding J, Baer MR, Hess JR, Zimrin AB.

Am J Hematol. 2018 Mar;93(3):E77-E79. doi: 10.1002/ajh.25007. Epub 2018 Jan 10. No abstract available.

33.

Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.

Emadi A, Law JY, Strovel ET, Lapidus RG, Jeng LJB, Lee M, Blitzer MG, Carter-Cooper BA, Sewell D, Van Der Merwe I, Philip S, Imran M, Yu SL, Li H, Amrein PC, Duong VH, Sausville EA, Baer MR, Fathi AT, Singh Z, Bentzen SM.

Cancer Chemother Pharmacol. 2018 Jan;81(1):217-222. doi: 10.1007/s00280-017-3459-6. Epub 2017 Nov 8.

PMID:
29119293
34.

Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.

Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR.

Clin Cancer Res. 2018 Jan 1;24(1):234-247. doi: 10.1158/1078-0432.CCR-17-1629. Epub 2017 Oct 26.

35.

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.

Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA.

Blood Adv. 2017 Jan 24;1(5):331-340. doi: 10.1182/bloodadvances.2016003053.

36.

Medial patellofemoral ligament reconstruction: patient selection and perspectives.

Baer MR, Macalena JA.

Orthop Res Rev. 2017 Sep 7;9:83-91. doi: 10.2147/ORR.S118672. eCollection 2017. Review.

37.

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M.

Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jul;19(7):e335. Lancet Oncol. 2019 Jun;20(6):e293.

38.

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.

Larrosa-Garcia M, Baer MR.

Mol Cancer Ther. 2017 Jun;16(6):991-1001. doi: 10.1158/1535-7163.MCT-16-0876. Review.

39.

Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.

Zou YS, Hoppman NL, Singh ZN, Sawhney S, Kotiah SD, Baer MR.

Cancer Genet. 2017 Apr;212-213:38-44. doi: 10.1016/j.cancergen.2017.03.004. Epub 2017 Mar 27.

PMID:
28449810
40.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

41.

Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.

Eisfeld AK, Kohlschmidt J, Schwind S, Nicolet D, Blachly JS, Orwick S, Shah C, Bainazar M, Kroll KW, Walker CJ, Carroll AJ, Powell BL, Stone RM, Kolitz JE, Baer MR, de la Chapelle A, Mrózek K, Byrd JC, Bloomfield CD.

Leukemia. 2017 Jun;31(6):1278-1285. doi: 10.1038/leu.2016.332. Epub 2016 Nov 15.

42.

Isolated thrombocytopenia and liver function abnormalities characterizing an atypical presentation of thrombotic thrombocytopenic purpura.

Bansal R, Baer MR, Zimrin AB, Law JY.

Ann Hematol. 2016 Dec;95(12):2079-2080. Epub 2016 Aug 20. No abstract available.

PMID:
27542956
43.

Use of the APACHE II score to assess impact of therapeutic plasma exchange for critically ill patients with hypertriglyceride-induced pancreatitis.

Nakhoda S, Zimrin AB, Baer MR, Law JY.

Transfus Apher Sci. 2017 Apr;56(2):123-126. doi: 10.1016/j.transci.2016.10.005. Epub 2016 Oct 17.

PMID:
27789124
44.

Concomitant amplification of the MLL gene on a ring chromosome and a homogeneously staining region (hsr) in acute myeloid leukemia: mechanistic implications.

Koka R, Mainor CB, Banerjee A, Baer MR, Zou YS.

Leuk Lymphoma. 2017 May;58(5):1250-1253. doi: 10.1080/10428194.2016.1233539. Epub 2016 Oct 12. No abstract available.

PMID:
27733077
45.

Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.

Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, Bellani M, Zou Y, Singh ZN, Duong VH, Rutherford T, Nagaria P, Bentzen SM, Seidman MM, Baer MR, Lapidus RG, Baylin SB, Rassool FV.

Cancer Cell. 2016 Oct 10;30(4):637-650. doi: 10.1016/j.ccell.2016.09.002.

46.

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).

Blum W, Sanford BL, Klisovic R, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wang ES, Hoke E, Mrózek K, Kohlschmidt J, Bloomfield CD, Geyer S, Marcucci G, Stone RM, Larson RA; Alliance for Clinical Trials in Oncology.

Leukemia. 2017 Jan;31(1):34-39. doi: 10.1038/leu.2016.252. Epub 2016 Sep 13.

47.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE.

Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8.

48.

Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.

Doshi KA, Trotta R, Natarajan K, Rassool FV, Tron AE, Huszar D, Perrotti D, Baer MR.

Oncotarget. 2016 Jul 26;7(30):48280-48295. doi: 10.18632/oncotarget.10209.

49.

Development of Hypercalcemia in a Patient Receiving Peginterferon alfa-2a Therapy for Polycythemia Vera.

Karne S, Mainor CB, Baer MR.

Pharmacotherapy. 2016 Jun;36(6):e54-e57. doi: 10.1002/phar.1767. Epub 2016 Jun 8.

PMID:
27150448
50.

Sex-specific patterns and differences in dementia and Alzheimer's disease using informatics approaches.

Ronquillo JG, Baer MR, Lester WT.

J Women Aging. 2016;28(5):403-11. doi: 10.1080/08952841.2015.1018038. Epub 2016 Apr 22.

Supplemental Content

Support Center